ClinicalTrials.gg
RecruitingNCT07619872KONECTIONUpdated Oct 2, 2026

KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance

An observational study in Aortic Valve Disease, sponsored by Edwards Lifesciences. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Edwards Lifesciences · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 2, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Aortic Valve Disease by Edwards Lifesciences — 3 open to participants now, 4 under way, none of them phase 3. Aortic Valve Disease · Edwards Lifesciences.

Started
2026
the only one that year
Observational
5 of 16
2 open now
Registered
16th of 16
by date

Among the 16 studies in Aortic Valve Disease by Edwards Lifesciences, this one is the only one that started in 2026, is one of 5 observational ones, and was the 16th registered.

Aortic Valve Disease

235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

3 of the 16 studies in Aortic Valve Disease by Edwards Lifesciences are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Aortic Valve Disease by Edwards Lifesciences, or all of them as a file.
02

Study summary

KONECTION is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in up to 250 participants who will receive the KONECT RESILIA aortic valved conduit, Model 11060A.

Read the detailed description

Subjects in the KONECTION study will be enrolled at up to 20 sites in Europe and Canada. The population will be participants requiring replacement of their diseased native or prosthetic aortic valve, and the associated repair or replacement of a damaged or diseased ascending aorta.

03

Conditions studied

  • Aortic Valve Disease

Browse trials for

Keywords

  • Bentall
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The target population includes adult candidates who require replacement of their native or prosthetic aortic valve, and the associated repair or replacement of a damaged or diseased ascending aorta.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years or older at the time of
  2. Have a diseased native or prosthetic aortic valve and a damaged or diseased ascending aorta that requires aortic valved conduit replacement surgery with the KONECT RESILIA AVC
  3. Provide written informed consent
  4. Willing to follow protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Active endocarditis or endocarditis within 3 months prior to the study index procedure
  2. Emergency procedure
  3. Stage 4 renal disease (estimated [eGFR] \<30 excluded) or requiring dialysis
  4. Less than 2-year due to non-cardiovascular life-threatening disease in the opinion of the study investigator
  5. High predicted risk of mortality prior to the procedure: Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) ≥8%
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Edwards KONECT RESILIA AVC

    Subjects who were treated with the Edwards KONECT RESILIA AVC

    Device: Edwards KONECT RESILIA AVC

Interventions

  • DeviceEdwards KONECT RESILIA AVC

    Surgical replacement of the aortic valve and ascending aorta with the Edwards KONECT RESILIA AVC

06

What researchers measure

Primary outcomes

  1. Percentage of participant's freedom from death and/or device related reintervention

    Participants' freedom from valve-related death or valve- and/or graft-related reintervention. Time to events were estimated by Kaplan-Meier method.

    Time frame: ≤ 30 days

Secondary outcomes

  1. Participant's linearized rate of thromboembolism

    A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.

    Time frame: Events occurring ≥ 31 days and up through 5 years post-implant

  2. Participant's linearized rate of valve thrombosis

    A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.

    Time frame: Events occurring ≥ 31 days and up through 5 years post-implant

  3. Participant's linearized rate of major paravalvular leak

    A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.

    Time frame: Events occurring ≥ 31 days and up through 5 years post-implant

  4. Participant's linearized rate of endocarditis

    A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.

    Time frame: Events occurring ≥ 31 days and up through 5 years post-implant

  5. Participant's linearized rate of major hemorrhage

    A linearized rate percentage is calculated by the following equation: \[(Total number of late adverse events in each category/total number of late patient years) x 100\]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact.

    Time frame: Events occurring ≥ 31 days and up through 5 years post-implant

  6. Percentage of participant's with freedom from death and/or device related reintervention

    Participants' freedom from valve-related death or valve- and/or graft-related reintervention. Time to events were estimated by Kaplan-Meier method.

    Time frame: 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up

  7. Participant's functional improvement over time from baseline for New York Heart Association (NYHA) Class

    The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity. Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present even at rest.

    Time frame: Baseline, 1 month, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up

  8. Participant's average mean gradient measurement over time

    Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

    Time frame: 1 month, 1-, 3-, and 5- Years follow-up

  9. Participant's average peak gradient measurement over time

    Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.

    Time frame: 1 month, 1-, 3-, and 5- Years follow-up

  10. Participant's average Effective Orifice Area (EOA) measurement over time

    Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.

    Time frame: 1 month, 1-, 3-, and 5- Years follow-up

  11. Participant's average Effective Orifice Area Index (EOAI) measurement over time

    Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve.

    Time frame: 1 month, 1-, 3-, and 5- Years follow-up

07

Study locations

3 of 3 sites recruiting
  • TUM Klinikum Deutsches Herzzentrum
    München, Bavaria 80636, Germany
    Recruiting
    • Markus Krane, Prof. Dr. med. · Principal investigator
  • Universitätsklinikum Bonn
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
    • Farhad Bakhtiary, Prof. Dr. med. · Principal investigator
  • Deutsches Herzzentrum der Charité
    Berlin, 13353, Germany
    Recruiting
    • Herko Grubitzsch, PD Dr. med. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be available to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2028, 30 months after the start.

Of 56 observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 97. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 2, 2026
StartActual
Jun 25, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jun 30, 2039
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Germany)
  • Universitätsklinikum Bonn · Bonn, Germany
  • Deutsches Herzzentrum der Charité · Berlin, Germany
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    2 sites added
    Show 2 added (2 Germany)
    • Universitätsklinikum Bonn · Bonn, Germany
    • Deutsches Herzzentrum der Charité · Berlin, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07619872
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Jun 25, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2039 (estimated)
Last update
Oct 2, 2026

Study contacts

Sabrina Hundt, PhD
Contact
Sabrina_Hundt@edwards.com
+49 (0)151 67550601
Markus Krane, Prof. Dr. med.
principal investigator · TUM Universitätsklinikum Deutsches Herzzentrum

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion